Research ExplorerPublicationsLoss of PSP94 expression is associated with early PSA recurr...

Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers

Standard

Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers. / Luebke, Andreas M; Attarchi-Tehrani, Ali; Meiners, Jan; Hube-Magg, Claudia; Lang, Dagmar S; Kluth, Martina; Tsourlakis, Maria Christina; Minner, Sarah; Simon, Ronald; Sauter, Guido; Büscheck, Franziska; Jacobsen, Frank; Hinsch, Andrea; Steurer, Stefan; Schlomm, Thorsten; Huland, Hartwig; Graefen, Markus; Haese, Alexander; Heinzer, Hans; Clauditz, Till S; Burandt, Eike; Wilczak, Waldemar; Höflmayer, Doris.

In: CANCER BIOL MED, Vol. 16, No. 2, 05.2019, p. 319-330.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Luebke, AM, Attarchi-Tehrani, A, Meiners, J, Hube-Magg, C, Lang, DS, Kluth, M, Tsourlakis, MC, Minner, S, Simon, R, Sauter, G, Büscheck, F, Jacobsen, F, Hinsch, A, Steurer, S, Schlomm, T, Huland, H, Graefen, M, Haese, A, Heinzer, H, Clauditz, TS, Burandt, E, Wilczak, W & Höflmayer, D 2019, 'Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers', CANCER BIOL MED, vol. 16, no. 2, pp. 319-330. https://doi.org/10.20892/j.issn.2095-3941.2018.0384

APA

Luebke, A. M., Attarchi-Tehrani, A., Meiners, J., Hube-Magg, C., Lang, D. S., Kluth, M., Tsourlakis, M. C., Minner, S., Simon, R., Sauter, G., Büscheck, F., Jacobsen, F., Hinsch, A., Steurer, S., Schlomm, T., Huland, H., Graefen, M., Haese, A., Heinzer, H., ... Höflmayer, D. (2019). Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers. CANCER BIOL MED, 16(2), 319-330. https://doi.org/10.20892/j.issn.2095-3941.2018.0384

Vancouver

Luebke AM, Attarchi-Tehrani A, Meiners J, Hube-Magg C, Lang DS, Kluth M et al. Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers. CANCER BIOL MED. 2019 May;16(2):319-330. https://doi.org/10.20892/j.issn.2095-3941.2018.0384

Bibtex

@article{042ca5abdf0d4d5aa6706e68a545eaa6,
title = "Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers",
abstract = "Objective: Prostate secretory protein of 94 amino acids (PSP94) is a target gene of the EZH2 transcriptional repressor and is often downregulated in prostate cancer; however, its prognostic value is disputed.Methods: Immunohistochemical analysis of a tissue microarray of 12, 432 prostate cancer specimens was performed to evaluate PSP94 expression. Correlation of PSP94 expression with tumor phenotype, patient prognosis, TMPRSS2:ERG fusion status, EZH2 expression and PTEN deletion was studied.Results: PSP94 expression was increased in benign prostatic hyperplasia; however, it was downregulated in 48% and negative in 42% of the 9, 881 interpretable prostate cancer specimens. The loss of PSP94 expression was inversely correlated to EZH2 expression (P < 0.0001) and largely unrelated to the ERG status, but strongly correlated with high Gleason grade, advanced tumor stage, and nodal metastasis ( P <0.0001 each). The fraction of PSP94-negative cancer specimens increased from 40% in pT2 to 52% in pT3b-pT4 ( P < 0.0001) and from 40% in Gleason 3+3 = 6 to 46% in Gleason 4+3 = 7 and 60% in Gleason ≥4+4 = 8 ( P < 0.0001). Loss of PSP94 was linked to early prostate-specific antigen recurrence, but with little absolute effect ( P < 0.0001). However, it provided additional prognostic impact in cancer specimens with PTEN deletion. Loss of PSP94 deteriorated prognosis of cancer patients with PTEN deletion by more than 10% (P < 0.0001). The combination of PTEN deletion and PSP94 loss provided independent prognostic information that was observed in several subgroups defined by classical and quantitative Gleason grade.Conclusions: The results of our study suggest that combined PSP94/PTEN analysis can be potentially used in the clinical prognosis of prostate cancer.",
author = "Luebke, {Andreas M} and Ali Attarchi-Tehrani and Jan Meiners and Claudia Hube-Magg and Lang, {Dagmar S} and Martina Kluth and Tsourlakis, {Maria Christina} and Sarah Minner and Ronald Simon and Guido Sauter and Franziska B{\"u}scheck and Frank Jacobsen and Andrea Hinsch and Stefan Steurer and Thorsten Schlomm and Hartwig Huland and Markus Graefen and Alexander Haese and Hans Heinzer and Clauditz, {Till S} and Eike Burandt and Waldemar Wilczak and Doris H{\"o}flmayer",
year = "2019",
month = may,
doi = "10.20892/j.issn.2095-3941.2018.0384",
language = "English",
volume = "16",
pages = "319--330",
journal = "CANCER BIOL MED",
issn = "2095-3941",
publisher = "Chinese Anticancer Association",
number = "2",

}

RIS

TY - JOUR

T1 - Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers

AU - Luebke, Andreas M

AU - Attarchi-Tehrani, Ali

AU - Meiners, Jan

AU - Hube-Magg, Claudia

AU - Lang, Dagmar S

AU - Kluth, Martina

AU - Tsourlakis, Maria Christina

AU - Minner, Sarah

AU - Simon, Ronald

AU - Sauter, Guido

AU - Büscheck, Franziska

AU - Jacobsen, Frank

AU - Hinsch, Andrea

AU - Steurer, Stefan

AU - Schlomm, Thorsten

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Haese, Alexander

AU - Heinzer, Hans

AU - Clauditz, Till S

AU - Burandt, Eike

AU - Wilczak, Waldemar

AU - Höflmayer, Doris

PY - 2019/5

Y1 - 2019/5

N2 - Objective: Prostate secretory protein of 94 amino acids (PSP94) is a target gene of the EZH2 transcriptional repressor and is often downregulated in prostate cancer; however, its prognostic value is disputed.Methods: Immunohistochemical analysis of a tissue microarray of 12, 432 prostate cancer specimens was performed to evaluate PSP94 expression. Correlation of PSP94 expression with tumor phenotype, patient prognosis, TMPRSS2:ERG fusion status, EZH2 expression and PTEN deletion was studied.Results: PSP94 expression was increased in benign prostatic hyperplasia; however, it was downregulated in 48% and negative in 42% of the 9, 881 interpretable prostate cancer specimens. The loss of PSP94 expression was inversely correlated to EZH2 expression (P < 0.0001) and largely unrelated to the ERG status, but strongly correlated with high Gleason grade, advanced tumor stage, and nodal metastasis ( P <0.0001 each). The fraction of PSP94-negative cancer specimens increased from 40% in pT2 to 52% in pT3b-pT4 ( P < 0.0001) and from 40% in Gleason 3+3 = 6 to 46% in Gleason 4+3 = 7 and 60% in Gleason ≥4+4 = 8 ( P < 0.0001). Loss of PSP94 was linked to early prostate-specific antigen recurrence, but with little absolute effect ( P < 0.0001). However, it provided additional prognostic impact in cancer specimens with PTEN deletion. Loss of PSP94 deteriorated prognosis of cancer patients with PTEN deletion by more than 10% (P < 0.0001). The combination of PTEN deletion and PSP94 loss provided independent prognostic information that was observed in several subgroups defined by classical and quantitative Gleason grade.Conclusions: The results of our study suggest that combined PSP94/PTEN analysis can be potentially used in the clinical prognosis of prostate cancer.

AB - Objective: Prostate secretory protein of 94 amino acids (PSP94) is a target gene of the EZH2 transcriptional repressor and is often downregulated in prostate cancer; however, its prognostic value is disputed.Methods: Immunohistochemical analysis of a tissue microarray of 12, 432 prostate cancer specimens was performed to evaluate PSP94 expression. Correlation of PSP94 expression with tumor phenotype, patient prognosis, TMPRSS2:ERG fusion status, EZH2 expression and PTEN deletion was studied.Results: PSP94 expression was increased in benign prostatic hyperplasia; however, it was downregulated in 48% and negative in 42% of the 9, 881 interpretable prostate cancer specimens. The loss of PSP94 expression was inversely correlated to EZH2 expression (P < 0.0001) and largely unrelated to the ERG status, but strongly correlated with high Gleason grade, advanced tumor stage, and nodal metastasis ( P <0.0001 each). The fraction of PSP94-negative cancer specimens increased from 40% in pT2 to 52% in pT3b-pT4 ( P < 0.0001) and from 40% in Gleason 3+3 = 6 to 46% in Gleason 4+3 = 7 and 60% in Gleason ≥4+4 = 8 ( P < 0.0001). Loss of PSP94 was linked to early prostate-specific antigen recurrence, but with little absolute effect ( P < 0.0001). However, it provided additional prognostic impact in cancer specimens with PTEN deletion. Loss of PSP94 deteriorated prognosis of cancer patients with PTEN deletion by more than 10% (P < 0.0001). The combination of PTEN deletion and PSP94 loss provided independent prognostic information that was observed in several subgroups defined by classical and quantitative Gleason grade.Conclusions: The results of our study suggest that combined PSP94/PTEN analysis can be potentially used in the clinical prognosis of prostate cancer.

U2 - 10.20892/j.issn.2095-3941.2018.0384

DO - 10.20892/j.issn.2095-3941.2018.0384

M3 - SCORING: Journal article

C2 - 31516752

VL - 16

SP - 319

EP - 330

JO - CANCER BIOL MED

JF - CANCER BIOL MED

SN - 2095-3941

IS - 2

ER -